ACADIA Pharmaceuticals
Market Cap
US$6.3b
Last Updated
2020/04/04 05:13 UTC
Data Sources
Company Financials +
Executive Summary
ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of small molecule drugs that address unmet medical needs in central nervous system disorders.
Rewards
Risk Analysis
Snowflake Analysis
Exceptional growth potential with excellent balance sheet.
Share Price & News
How has ACADIA Pharmaceuticals's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: ACAD has not had significant price volatility in the past 3 months.
Market Performance
7 Day Return
5.0%
ACAD
2.5%
US Biotechs
-2.0%
US Market
1 Year Return
45.0%
ACAD
-0.9%
US Biotechs
-15.1%
US Market
Return vs Industry: ACAD exceeded the US Biotechs industry which returned -0.9% over the past year.
Return vs Market: ACAD exceeded the US Market which returned -15.1% over the past year.
Shareholder returns
| ACAD | Industry | Market | |
|---|---|---|---|
| 7 Day | 5.0% | 2.5% | -2.0% |
| 30 Day | -8.2% | -8.3% | -19.7% |
| 90 Day | 1.0% | -4.1% | -23.2% |
| 1 Year | 45.0%45.0% | -0.2%-0.9% | -13.4%-15.1% |
| 3 Year | 26.0%26.0% | 13.8%10.9% | 10.9%3.7% |
| 5 Year | 8.6%8.6% | -7.2%-11.6% | 28.4%14.4% |
Price Volatility Vs. Market
How volatile is ACADIA Pharmaceuticals's share price compared to the market and industry in the last 5 years?
Simply Wall St News
2 weeks ago | Simply Wall St
We're Excited To See How ACADIA Pharmaceuticals (NASDAQ:ACAD) Uses Its Cash Hoard To Grow1 month ago | Simply Wall St
ACADIA Pharmaceuticals Inc. Just Reported Full-Year Earnings: Have Analysts Changed Their Mind On The Stock?1 month ago | Simply Wall St
ACADIA Pharmaceuticals Inc.'s (NASDAQ:ACAD) Profit OutlookValuation
Is ACADIA Pharmaceuticals undervalued compared to its fair value and its price relative to the market?
>50%
Undervalued compared to fair value
Share Price vs. Fair Value
Below Fair Value: ACAD ($40.76) is trading below our estimate of fair value ($114.87)
Significantly Below Fair Value: ACAD is trading below fair value by more than 20%.
Price To Earnings Ratio
PE vs Industry: ACAD is unprofitable, so we can't compare its PE Ratio to the Biotechs industry average.
PE vs Market: ACAD is unprofitable, so we can't compare its PE Ratio to the US market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate ACAD's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: ACAD is overvalued based on its PB Ratio (9.1x) compared to the US Biotechs industry average (2.5x).
Next Steps
Future Growth
How is ACADIA Pharmaceuticals forecast to perform in the next 1 to 3 years based on estimates from 15 analysts?
57.8%
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: ACAD is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (1.7%).
Earnings vs Market: ACAD is forecast to become profitable over the next 3 years, which is considered above average market growth.
High Growth Earnings: ACAD's is expected to become profitable in the next 3 years.
Revenue vs Market: ACAD's revenue (34.4% per year) is forecast to grow faster than the US market (7.1% per year).
High Growth Revenue: ACAD's revenue (34.4% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: ACAD's Return on Equity is forecast to be high in 3 years time (37.8%)
Next Steps
Past Performance
How has ACADIA Pharmaceuticals performed over the past 5 years?
-13.1%
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: ACAD is currently unprofitable.
Growing Profit Margin: ACAD is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: ACAD is unprofitable, and losses have increased over the past 5 years at a rate of -13.1% per year.
Accelerating Growth: Unable to compare ACAD's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: ACAD is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (22%).
Return on Equity
High ROE: ACAD has a negative Return on Equity (-33.65%), as it is currently unprofitable.
Next Steps
Financial Health
How is ACADIA Pharmaceuticals's financial position?
Financial Position Analysis
Short Term Liabilities: ACAD's short term assets ($760.3M) exceed its short term liabilities ($74.8M).
Long Term Liabilities: ACAD's short term assets ($760.3M) exceed its long term liabilities ($9.2M).
Debt to Equity History and Analysis
Debt Level: ACAD is debt free.
Reducing Debt: ACAD has not had any debt for past 5 years.
Balance Sheet
Inventory Level: ACAD has a low level of unsold assets or inventory.
Debt Coverage by Assets: Insufficient data to determine if ACAD's debt is covered by short term assets.
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: ACAD has sufficient cash runway for more than 3 years based on its current free cash flow.
Forecast Cash Runway: Insufficient data to determine if ACAD has enough cash runway if its free cash flow continues to grow or shrink based on historical rates.
Next Steps
Dividend
What is ACADIA Pharmaceuticals's current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate ACAD's dividend yield against the bottom 25% of dividend payers, as the company has not reported any payouts.
High Dividend: Unable to evaluate ACAD's dividend yield against the top 25% of dividend payers, as the company has not reported any payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if ACAD's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if ACAD's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of ACAD's dividend in 3 years as they are not forecast to pay a notable one for the US market.
Next Steps
Management
How experienced are the management team and are they aligned to shareholders interests?
1.7yrs
Average management tenure
CEO
Steve Davis (58yo)
4.58s
Tenure
US$6,508,032
Compensation
Mr. Stephen R. Davis, also known as Steve, J.D., serves as the Director at Heron Therapeutics Inc. since October 2019. He has been the Chief Executive Officer of ACADIA Pharmaceuticals, Inc. since Septembe ...
CEO Compensation Analysis
Compensation vs Market: Steve's total compensation ($USD6.51M) is about average for companies of similar size in the US market ($USD7.63M).
Compensation vs Earnings: Steve's compensation has been consistent with company performance over the past year.
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO & Director | 4.58yrs | US$6.51m | 0.0019% $120.3k | |
| President | 1.42yrs | US$5.68m | 0.0039% $245.7k | |
| Executive VP | 1.75yrs | US$2.13m | 0.00033% $20.9k | |
| Executive VP & Chief Commercial Officer | 3.08yrs | US$3.18m | 0.0016% $101.9k | |
| Executive VP | 1.5yrs | no data | no data | |
| Senior Vice President of Strategy & Technology Operations | no data | no data | no data | |
| Senior VP | 1.58yrs | no data | no data | |
| Vice President of Investor Relations | no data | no data | no data | |
| Chief Compliance Officer & VP | 4.67yrs | no data | no data | |
| Senior VP of Corporate Affairs & Chief Communications Officer | 0.33yr | no data | no data |
1.7yrs
Average Tenure
57.5yo
Average Age
Experienced Management: ACAD's management team is not considered experienced ( 1.7 years average tenure), which suggests a new team.
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO & Director | 4.58yrs | US$6.51m | 0.0019% $120.3k | |
| Independent Director | 11.92yrs | US$793.63k | no data | |
| Independent Director | 4.33yrs | US$231.28k | 0.066% $4.2m | |
| Member of the Scientific and Clinical Advisory Board | no data | no data | no data | |
| Independent Director | 4.42yrs | US$394.55k | 0.00064% $40.5k | |
| Independent Director | 5.08yrs | US$412.57k | 0.0064% $407.8k | |
| Member of the Scientific and Clinical Advisory Board | no data | no data | no data | |
| Member of the Scientific and Clinical Advisory Board | no data | no data | no data | |
| Member of the Scientific and Clinical Advisory Board | no data | no data | no data | |
| Independent Chairman of the Board | 3.83yrs | US$276.28k | no data |
4.5yrs
Average Tenure
62yo
Average Age
Experienced Board: ACAD's board of directors are considered experienced (4.5 years average tenure).
Ownership
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
Ownership Breakdown
Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 16.3%.
Top Shareholders
Company Information
ACADIA Pharmaceuticals Inc.'s company bio, employee growth, exchange listings and data sources
Key Information
- Name: ACADIA Pharmaceuticals Inc.
- Ticker: ACAD
- Exchange: NasdaqGS
- Founded: 1993
- Industry: Biotechnology
- Sector: Pharmaceuticals & Biotech
- Market Cap: US$6.332b
- Shares outstanding: 155.34m
- Website: https://www.acadia-pharm.com
Number of Employees
Location
- ACADIA Pharmaceuticals Inc.
- 3611 Valley Centre Drive
- Suite 300
- San Diego
- California
- 92130
- United States
Listings
| Ticker | Exchange | Primary Security | Security Type | Country | Currency | Listed on |
|---|---|---|---|---|---|---|
| ACAD | NasdaqGS (Nasdaq Global Select) | Yes | Common Stock | US | USD | May 2004 |
| DR6 | DB (Deutsche Boerse AG) | Yes | Common Stock | DE | EUR | May 2004 |
| DR6 | BRSE (Berne Stock Exchange) | Yes | Common Stock | CH | CHF | May 2004 |
| ACAD * | BMV (Bolsa Mexicana de Valores) | Yes | Common Stock | MX | MXN | May 2004 |
Biography
ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of small molecule drugs that address unmet medical needs in central nervous system disorders. The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson’s disease psychosis. It is also developing pimavanserin as a treatment for dementia-related psychosis and as an adjunctive treatment for schizophrenia that are in Phase III clinical trials; and pimavanserin as an adjunctive treatment for major depressive disorder. ACADIA Pharmaceuticals Inc. was founded in 1993 and is headquartered in San Diego, California.
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2020/04/04 05:13 |
| End of Day Share Price | 2020/04/03 00:00 |
| Earnings | 2019/12/31 |
| Annual Earnings | 2019/12/31 |
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.